A review of nelfinavir for the treatment of HIV infection

被引：9

作者：

Olmo, Montserrat ^{[1
]}

Podzamczer, Daniel ^{[1
]}

机构：

[1] Hosp Univ Bellvitge, HIV Unit, Infect Dis Serv, Barcelona 08907, Spain

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2006年 / 2卷 / 02期

关键词：

HIV infection; nelfinavir; protease inhibitor;

D O I：

10.1517/17425255.2.2.285

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Nelfinavir (NFV) is a protease inhibitor that has been widely used for several years for the treatment of HIV infection. This has led to extensive experience with NFV-containing regimens, in which the drug has shown prolonged viral suppression, good tolerability and a unique resistance profile. In recent years, several antiretroviral drugs with some advantages over NFV have been developed. Nevertheless, NFV has favourable characteristics that make it a suitable antiretroviral compound for many HIV-infected patients. It can be used in patients who do not tolerate ritonavir even at low doses, and it is well tolerated in pregnant women, has a low-grade interaction with methadone and may be well tolerated in hepatitis C virus-co-infected patients. In addition, its new simplified posology may contribute to improved adherence.

引用

页码：285 / 300

页数：16

共 112 条

[11]

Bergshoeff AS, 2003, ANTIVIR THER, V8, P215

[12] Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use [J].

Bergshoeff, AS ;

Wolfs, TFW ;

Geelen, SPM ;

Burger, DM .

ANNALS OF PHARMACOTHERAPY, 2003, 37 (04) :521-525

[13] Sildenafil does not alter nelfinavir pharmacokinetics [J].

Bratt, G ;

Ståhle, L .

THERAPEUTIC DRUG MONITORING, 2003, 25 (02) :240-242

[14]

BROWN LS, 2001, 41 INT C ANT AG CHEM

[15]

BRYSON J, 2002, 9 C RETR OP INF SEAT

[16] Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children [J].

Burger, DM ;

Bergshoeff, AS ;

De Groot, R ;

Gibb, D ;

Walker, S ;

Tréluyer, JM ;

Hoetelmans, RMW .

JOURNAL OF PEDIATRICS, 2004, 145 (03) :403-405

[17] Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations [J].

Burger, DM ;

Hugen, PWH ;

Aarnoutse, RE ;

Hoetelmans, RMW ;

Jambroes, M ;

Nieuwkerk, PT ;

Schreij, G ;

Schneider, MME ;

van der Ende, ME ;

Lange, JMA .

THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :73-80

[18] Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy) [J].

Casado, A ;

Badia, X ;

Consiglio, E ;

Ferrer, E ;

González, A ;

Pedrol, E ;

Gatell, JM ;

Azuaje, C ;

Llibre, JM ;

Aranda, M ;

Barrufet, P ;

Martínez-Lacasa, J ;

Podzamczer, D .

HIV CLINICAL TRIALS, 2004, 5 (03) :132-139

[19] Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen [J].

Casado, JL ;

Moreno, S ;

Hertogs, K ;

Dronda, F ;

Antela, A ;

Dehertogh, P ;

Perez-Elías, MJ ;

Moreno, A .

AIDS, 2002, 16 (01) :47-52

[20] Risk of birth defects associated with nelfinavir exposure during pregnancy [J].

Covington, DL ;

Conner, SD ;

Doi, PA ;

Swinson, J ;

Daniels, EM .

OBSTETRICS AND GYNECOLOGY, 2004, 103 (06) :1181-1189

← 1 2 3 4 5 6 7 8 9 10 →